
FOLLOWUS
1. China Academy of TCM, Xiyuan Hospital,Beijing
2. Institute of Basic Medicine, PUMC, Academy of Chinese Medical Sciences,China
Published:2000,
Scan for full text
Li, Y., Wang, Z., Weng, J. et al. Effect of xuefu zhuyu decoction on the function of platelets and human umbilical vein endothelial cell., CJIM 6, 254–257 (2000). https://doi.org/10.1007/BF02947371
Yanmei Li, Zhong Wang, Jin Weng, et al. Effect of xuefu zhuyu decoction on the function of platelets and human umbilical vein endothelial cell. [J]. Chinese Journal of Integrative Medicine 6(4):254-257(2000)
Li, Y., Wang, Z., Weng, J. et al. Effect of xuefu zhuyu decoction on the function of platelets and human umbilical vein endothelial cell., CJIM 6, 254–257 (2000). https://doi.org/10.1007/BF02947371 DOI:
Yanmei Li, Zhong Wang, Jin Weng, et al. Effect of xuefu zhuyu decoction on the function of platelets and human umbilical vein endothelial cell. [J]. Chinese Journal of Integrative Medicine 6(4):254-257(2000) DOI: 10.1007/BF02947371.
Objective: To explore the effect of Xuefu Zhuyu Decoction (XZD) on molecular expression of platelets glycoprotein II b/III a complex (GP II b/III a) and thrombomodulin (TM) of human umbilical vein endothelial cells.Methods: Platelets and human umbilical vein endothelial cells were incubated with XZD of different concentration. GP II b/III a and TM were evaluated by radioimmunoassay.Results: XZD in 40 mg/ml and 80 mg/ml could obviously inhibit the adenosine diphosphate induced GII b/III a complex expression
the molecular number being 52900 ± 8445 and 52095 ± 6345 respectively
and there was significant difference as comparing with that in the control group ( P < 0.05
P<0.01). But XZD didn’t show any influence on the molecular expression of TM in human umbilical vein endothelial cells.Conclusion: XZD could inhibit the adenosine diphosphate induced activation of platete through blocking the exposure of GII b/III a a complex.
Objective: To explore the effect of Xuefu Zhuyu Decoction (XZD) on molecular expression of platelets glycoprotein II b/III a complex (GP II b/III a) and thrombomodulin (TM) of human umbilical vein endothelial cells.Methods: Platelets and human umbilical vein endothelial cells were incubated with XZD of different concentration. GP II b/III a and TM were evaluated by radioimmunoassay.Results: XZD in 40 mg/ml and 80 mg/ml could obviously inhibit the adenosine diphosphate induced GII b/III a complex expression
the molecular number being 52900 ± 8445 and 52095 ± 6345 respectively
and there was significant difference as comparing with that in the control group ( P < 0.05
P<0.01). But XZD didn’t show any influence on the molecular expression of TM in human umbilical vein endothelial cells.Conclusion: XZD could inhibit the adenosine diphosphate induced activation of platete through blocking the exposure of GII b/III a a complex.
platelet glycoprotein II b/III a complexthrombomodulin (TM)kw]human umbilical vein endothelial cell
platelet glycoprotein II b/III a complexthrombomodulin (TM)kw]human umbilical vein endothelial cell
Mousa SA, Bennett JS, Platelets in health and disease: platelet GP II b/III a structure and function: recent advance in antiplatelet therapy. Drugs Future 1996; 21: 1141–1154.
Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Platelet Health Dis 1990;4:1–26.
Li Yanmei, Chen Keji, Zhang XW, et al. Effect of Xuefu Zhuyu pill on patients with carotid atherosclerosis by colour doppler ultrasonography. CJIM 1997; 17(3): 152–155.
LI Yanmei, Chen Keji, Shi ZX, et al. Effect of Xuefu Zhuyu pill on blood stasis syndrome and risk factor of atherosclerosis. CJIM 1998; 18(2): 71–73.
Shaker A, Mousa, Kamkapil, Dun-Xu. Atherosclerosis, thrombosis and vascular biology. Intravenous and oral antithrombotic efficacy of the novel platelet GP II b/III a antagonist roxifiban and its free acid form, XV459 atherosclerosis. Thrombosis and Vascular Biology 1999; 19(10): 2535 -2541.
Simoos ML, Van den Brand MJ. Randomized trial of a GP II b/III a platelet receptor blocker in refractory unstable angina. Circulation 1994; 89:596–603.
Carter AM, Ossei Gerning N, Wilson IJ, et al. Association of the platelet PIA polymorphism of Glycoprotein and fibrinogen Bb 448 polymarphism with myocardial infarction GP II b/III a and extent of coronary artery disease. Circulation 1997; 96:1424–1431.
Frishman WH, Burns B, Atac B, et al. Novel antiplatelet therapies for treatment of patients with ischemic heart disease inhibitors of platelet glycoprotein GP II b/III a integrin receptor. AM Heart J 1995:130:872–892.
Body SC. Platelet activation and interaction with microvasculature. J Cardiovasc Pharmacol 1996;27(suppl 1): 13–25.
Grines CL. Thrombolytic, antiplatelet and antithrombotic agents. Am J Cardiol 1992;70:18–26.
Salam HH. The natural anticoagulants. Clinics in Hematology 1986; 15(2): 371–391.
Maruyama I. Expression and distribution of thrombomodulin on altered endothelium. Thromb Haemost 1989; 62: 467.
0
Views
342
Downloads
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621